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Background: MICA/B are major ligands for NK cell activating receptor NKG2D and previous studies showed that
the serum level of soluble MICA (sMICA) is an independent prognostic factor for advanced human hepatocellular
carcinoma. However, the correlation between cellular MICA/B expression pattern and human hepatocellular
carcinoma progression has not been well explored. The unfolded protein response is one of the main causes of
resistance to chemotherapy and radiotherapy in tumor cells. However, whether the UPR in HCC could regulate the
expression levels of MICA/B and affect the sensitivity of HCC cells to NK cell cytolysis has not been established yet.
Methods: MICA/B expression pattern was evaluated by immunohistochemistry and Kaplan-Meier survival analysis
was done to explore the relationship between MICA/B expression level and patient survival. The protein and mRNA
expression levels of MICA/B in SMMC7721 and HepG2 cells treated by tunicamycin were evaluated by flow cytometry,
Western Blot and RT-PCR. The cytotoxicity analysis was performed with the CytoTox 96 Non-Radioactive LDH
Cytotoxicity Assay.
Results: MICA/B was highly expressed in human hepatocellular carcinoma and the expression level was
significantly and negatively associated with tumor-node metastasis (TNM) stages. Patients with low level of
MICA/B expression showed a trend of shorter survival time. The unfolded protein response (UPR) downregulated
the expression of MICA/B. This decreased protein expression occurred via post-transcriptional regulation and
was associated with proteasomal degradation. Moreover, decreased expression level of MICA/B led to the
attenuated sensitivity of human HCC to NK cell cytotoxicity.
Conclusion: These new findings of the connection of MICA/B, UPR and NK cells may represent a new concrete
theory of NK cell regulation in HCC, and suggest that targeting this novel NK cell-associated immune evasion
pathway may be meaningful in treating patients with HCC.
Keywords: MICA/B, Hepatocellular carcinoma, Natural killer cell, Unfolded protein response, Innate immunityIntroduction
Hepatocellular carcinoma (HCC) is the third most common
of cancer-related deaths worldwide and accounts for ap-
proximately 70%-80% of all primary liver cancer cases [1].
Currently, removal of the malignant tissue by surgical resec-
tion is the main line of treatment. However, recurrence is* Correspondence: immu_jin@fmmu.edu.cn; chenlh@fmmu.edu.cn
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unless otherwise stated.quite common in patients who have had a resection, and
the results of current therapy for advanced disease are
poor with 30%-40% 5 years survivals [2]. Prevention of
HCC progression and its recurrence is one of the most
challenging aspects for efficient cancer immunotherapy
of HCC.
NK cells mediate direct cytotoxic activity against tumor
cells and provide the early host defense against the neo-
plastic cells. Although there are enriched NK cells in
hepatoma tissues and NK cells within a healthy liver ex-
hibit a higher level of cytotoxicity against tumor cells andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pared with peripheral NK cells [3,4], hepatoma cells still
could escape from NK cell-mediated killing and survive.
We conjectured that there are likely undefined molecular
and cellular mechanisms by which hepatoma cells escape
from NK cell recognition and killing.
The interaction between NK cell activating receptors
and their ligands are known to modulate immune sur-
veillance and affect the tumor progression. Major histo-
compatibility complex class I-related chain A and B
(MICA/B) are two stress-inducible ligands that bind to
the immunoreceptor, NKG2D and play an important
role in mediating cytotoxicity of NK cells [5]. Although
expression of MICA/B in normal tissues is restricted
mainly to the thymus and gastrointestinal epithelium,
MICA/B were detected on several carcinoma cells such
as liver, lung, breast, ovary, prostate and colon cancer
[6,7]. The cell surface expression of MICA/B is regulated
by heat shock, viral or bacterial infections or pharmaco-
logical agents which are known to affect the antitumor
immunity [5,8,9]. This raises the possibility that MICA/B
may be specific targets on tumor cells for NK-mediated
cytolytic activity.
The unfolded protein response (UPR) is a consequence
of endoplasmic reticulum (ER) stress which is triggered
by accumulation of incorrect folding and improper glyco-
sylation of newly synthesized proteins in ER. The UPR in-
duced by the stressors contributes to the survival, growth,
progression and chemo-resistance of cancer [10]. It has
also been demonstrated that UPR may be a protective
mechanism for tumor. HCC progression is often accom-
panied by hypoxia, decreased glucose supply and in-
creased UPR in the tumor microenvironment [11-13].
However, whether the UPR in HCC could regulate the
expression levels of the ligands for NK cell activating re-
ceptors and affect the sensitivity to NK cell cytolysis has
not been established yet.
In this study, we systematically investigated the protein
expression of MICA/B in 5 normal liver tissues and 96 he-
patocellular carcinoma tissues. We also studied the value
of MICA/B for prognosis in HCC patients and showed
that the expression levels of MICA/B on hepatoma cells
were significantly down-regulated during UPR, which




The study was approved by the Ethics Committee at
FMMU, and informed consent was obtained from each
patient. A total of 96 histologically confirmed HCC
patients undergoing radical resection at 2008 were en-
rolled from Xijing hospital of the Fourth Military Medical
University. None of these patients had received any anti-cancer therapy before surgery. The TNM stage was deter-
mined according to the 7th edition UICC/AJCC staging
system. Patients were followed from the time of hospital
admission and first treatment until August, 2012. Overall
survival (OS), defined as the time from operation to death
or last follow-up, was used as a measure of prognosis.
Immunohistochemical (IHC) staining and evaluation
Immunohistochemical detection of MICA/B was done
as described previously [14,15]. Briefly, paraffin sections
of human hepatoma tissues were dewaxed, hydrated and
incubated in peroxidase inhibitor for 30 min to remove
endogenous peroxidase. The samples were then dipped
into rabbit anti-human MICA/B polyclonal antibody
(Abgent, diluted to 1:100) at 4°C overnight after blocking
with diluted goat serum (Sigma, MO, USA). Rabbit IgG
prior to immunization and antigen-absorbent immune
serum were applied as negative controls. After three washes
in PBS, the slices were dipped into HRP-conjugated goat
anti-mouse IgG/anti-rabbit IgG (Abcam, MA, UK) for
30 min at room temperature. The antibody complexes were
then visualized by incubation with diaminobenzidine
chromogen. The sections were counterstained with Mayer’s
hematoxylin for 2 min, dehydrated through a graded etha-
nol series, cleared in dimethyl benzene, mounted and ex-
amined using light microscopy (Olympus, Tokyo, Japan).
All slices were evaluated by two pathologists without
knowledge of the clinical outcome. The percentage of
immune-reactive cells and the staining intensities were
evaluated in each sample. The percentage of immune-
reactive cells was graded on a scale of 0 to 4, where no
staining was scored as 0; 1–10% of cells stained was scored
as 1; 11–50% was scored as 2; 51–80% was scored as 3; and
81–100% was scored as 4. The staining intensities were
graded from 0 to 3, where 0 was defined as negative; 1 as
weak; 2 as moderate; and 3 as strong. The total score was
calculated as the product of intensity and percentage
scores, ranging from 0 to 12. The expression level was di-
vided as low or high by the median total score.
Cell culture
NK cells used in functional experiments were isolated from
healthy donors and resuspended in complete medium
(RPMI 1640 containing 100 μg/ml L-glutamine, 10% heat-
inactivated FBS, 100 U/ml penicillin G, and 100 μg/ml
streptomycin) supplemented with 1000 IU/ml IL-2 and in-
cubated overnight at 37°C before use. SMMC7721 cells were
maintained in RPMI 1640 with 10% FBS and penicillin/
streptomycin, and HepG2 cells were maintained in DMEM
with 10% FBS and penicillin/streptomycin.
Flow cytometry, western blot and cytotoxicity analyses
SMMC7721 and HepG2 cells were stained with anti-
MICA/B (clone 6D4, Biolegend, CA, USA) for 30 min
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mouse IgG1κ mAb (BD Biosciences, NJ, USA) for 20 min
on ice. Mouse IgG1κ isotype control (BD Biosciences, NJ,
USA) was used as a negative control. A minimum of
20,000 gated events/sample was collected on a flow cyt-
ometer (FACSCalibur, Elite ESP, FL, USA) and analyzed
using CellQuest software. SMMC7721 and HepG2 cells
from different treatment groups were lysed in lysis buffer
(Bio-Rad, CA, USA), and the western blot analysis was
performed as described previously [10]. The cytotox-
icity analysis was performed with the CytoTox 96 Non-
Radioactive LDH Cytotoxicity Assay (Promega, WI, USA),
according to the protocol provided. To analyze the in-
volvement of MICA/B in cytolytic activity of NK cells,
anti-MICA/B mAb (6D4) or isotype-matched control Ab
was added during the cytolytic assay.Statistical analyses
Each experiment was performed independently at least
three times and one representative experiment is pre-
sented. All statistical analyses were performed using the
SPSS 13.0 statistical software package. Average values
are reported as the mean ± S.D. The significance of dif-
ferences was analyzed statistically by the compared t test
with Welch’s correction, or Mann-Whitney U test. The
correlation between MICA/B level and GRP78 level was
evaluated by correlation, and Pearson correlation coeffi-
cients were calculated to estimate the correlations. A
Kaplan-Meier survival function was calculated and com-
pared with a log-rank test to assess the differences of
OS. All statistical tests were 2-sided, and P-values <0.05
were considered significant.Figure 1 Immunohistochemical staining of MICA/B in HCC
patients with different clinical stages. (A) Representative
immune-histochemical staining of the expression of MICA/B in HCC
tissues. a, normal liver tissue; b, TNM stage I tumor tissue; c, TNM
stage II tumor tissue; d, TNM stage III tumor tissue; e, TNM stage IV
tumor tissue. (B) Immune-histochemical scores of MICA/B in HCC
tissues of different stages. Data were presented as means ± S.D.,
*P < 0.05, **P < 0.01.Results
Clinical significance of MICA/B expression profile in HCC
tissue
MICA/B expression pattern was evaluated by immunohis-
tochemistry in a retrospective cohort of HCC patients
after tumor resection. Among the 96 patients (Additional
file 1: Table S1), 75 patients (78%) showed positive MICA/
B expression in the cytoplasm and membrane (Figure 1A).
The other 21 patient samples showed no detectable
MICA/B expression. Additionally, MICA/B was not de-
tected in the surrounding non-cancerous tissues and nor-
mal hepatocellular tissues (Figure 1A). We also evaluated
the immunohistochemical score of MICA/B expression. It
was found that the expression level of MICA/B was sig-
nificantly higher in the hepatoma cells at early stages
(stages T1 and T2) compared to that of the hepatoma cells
at advanced tumor stages (stages T3 and T4) (Figure 1B).
These results suggested that MICA/B expression was sig-
nificantly and negatively associated with TNM stage in he-
patocellular carcinoma.Expression level of MICA/B was negatively associated
with the clinical outcome of HCC
To determine the prognostic value of MICA/B expres-
sion in hepatocellular carcinoma, the HCC patients were
divided into two groups by the MICA/B expression score.
Kaplan-Meier survival analysis was done to explore the
relationship between MICA/B expression level and pa-
tient survival. These results showed that patients with
high expression level of MICA/B had a longer overall
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test, P < 0.001) (Figure 2).
The expression of GRP78 was negatively correlated with
MICA/B expression level
HCC progression is often accompanied by hypoxia, de-
creased glucose supply and increased UPR in the tumor
microenvironment. As expected, the expression level of
GRP78, a molecular chaperone involved in the UPR, was
increased in the hepatoma tissues and significantly re-
lated with tumor TNM stage (Figure 3A). In contrast, the
GRP78 level was negatively correlated with MICA/B ex-
pression level (coefficient, -0.483; P < 0.001) (Figure 3B).
UPR downregulated MICA/B expression in HCC
To test the potential effect of HCC UPR on MICA/B ex-
pression, SMMC7721 and HepG2 hepatoma cell lines
were treated with tunicamycin (TM, a naturally occur-
ring antibiotic that induces ER stress by inhibiting the
first step in the biosynthesis of N-linked oligosaccharides
in cells ) for indicated times. Membrane-bound MICA/B
was consistently expressed at high levels in SMMC7721
and HepG2 cells. TM treatment resulted in a gradual de-
crease of their expression beginning at 16 hour post-
treatment. A significant reduction in both cell lines was
observed at 36 and 48 hour as measured by both the per-
centage of stained cells and by MFI (Figure 4A, and B).Figure 2 Kaplan-Meier survival curves of HCC patients with different
MICA/B had a better overall survival than those with low expression level oProtein expression levels of MICA/B detected by western
blot showed a similar pattern to that of the membrane-
bound molecules detected by flow cytometry (Figure 4C).
These results revealed that the UPR down-regulated total
and membrane protein expression of MICA/B.
Decreased expression of MICA/B occurred via
post-transcriptional regulation
When the mRNA level of MICA/B was analyzed, TM
treatment unexpectedly caused a gradual increase of
MICA/B mRNA level with a significant increase at 36 h
in SMMC7721 cells (Figure 5A). These results suggested
that their decreased protein expression did not result from
lowered transcript level, and might have occurred via
post-transcriptional regulation. We investigated whether
the protein degradation was a mechanism for decreased
MICA/B protein expression during UPR activation. It was
found that the proteasome inhibitor MG132 inhibited the
downregulation of MICA/B protein in SMMC7721 cells
induced by TM (Figure 5B), indicating that the decreased
expression of MICA/B in HCC during UPR was associ-
ated with proteasomal degradation. In support of this pos-
sibility, protein half-life analysis in the presence of the
protein synthesis inhibitor cycloheximide (CHX) showed
that the MICA/B turnover rate was more rapid in
SMMC7721 cells treated with TM as compared to cells
exposed to DMSO (Figure 5C).MICA/B expression levels. Patients with high expression level of
f MICA/B (log-rank test, P < 0.001).
Figure 3 Correlation of GRP78 and MICA/B expression levels in HCC patients. (A) Immunochemical staining scores of GRP78 expression in
human hepatoma tissues. Data were presented as means ± S.D., *P < 0.05, **P < 0.01. (B) Correlation between GRP78 scores and MICA/B scores in
hepatoma tissues. P < 0.001.
Figure 4 Decreased expression level of MICA/B on hepatoma cells following tunicamycin(TM) treatment. (A) Surface expression level of
MICA/B on SMMC7721 and HepG2 cells was analyzed using flow cytometry. The grey histograms represent the isotype control staining. (B) Upper
panel: data on the y-axes represent the mean percentage positive staining. Lower panel: data on the y-axes represent the mean florescence
intensity. Data were presented as means ± S.D., *P < 0.05, **P < 0.01. (C) Total protein expression level of MICA/B in SMMC7721 and HepG2 cells
treated with DMSO or TM for 16 or 24 h were analyzed using a western blot assay. GAPDH was detected as a loading control. The data shown
are representative of three individual experiments.
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Figure 5 Protein degradation was a mechanism for decreased
MICA/B protein expression during UPR activation. (A) Increased
expression level of MICA/B mRNA in SMMC7721 cells after the
treatment with TM for 24 h and 36 h. Bars represented the relative
quantities of MICA/B mRNA in SMMC7721 cells (mean and S.D.).
*P < 0.05. (B) The proteasome inhibitor MG132 reversed the
downregulation of MICA in hepatoma cells during UPR. SMMC7721
cells with or without pretreatment with the proteasome inhibitor
MG132 (10 mM) for 1 h were treated with TM (3 mM) for 24 h.
Total protein from whole-cell lysates was then subjected to western
blot analysis for MICA/B and GAPDH (as a loading control). The
data shown are representative of three individual experiments.
(C) UPR accelerated the turnover rate of MICA/B in hepatoma cells.
SMMC7721 cells were treated with the protein synthesis inhibitor
cycloheximide (CHX; 10 mg/ml) with or without the addition of TM
(3 mM) for the indicated periods. Total protein from whole-cell
lysates was then subjected to western blot analysis for MICA/B and
GAPDH (as a loading control). The data shown are representative of
three individual experiments.
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cell–mediated cytotoxicity
Because changes in the expression of NKG2D ligands
(such as MICA/B) on tumor cells can modify the recog-
nition and activation of NK cells via NKG2D, while the
previous result showed that TM reduced MICA/B levels,
we next tested whether treatment of HCC cells with TMcould also lead to decreased activation and NK cell-
mediated killing. The susceptibility of SMMC7721 cells
and HepG2 cells to NK cell cytolysis was determined
using the LDH cytotoxicity assay. We observed that TM
treatment reduced NK cytoxicity against SMMC7721 and
HepG2 cells. To confirm this decrease of cytotoxicity was
dependent on NKG2D/MICA/B interaction, we used a
blocking anti–MICA/B mAb to mask the cell-surface
MICA/B. This treatment significantly inhibited the cyto-
lytic activity of NK cells against SMMC7721 and HepG2
cells in comparison with that of control mAb, but the dif-
ferences of cytolytic activity between TM and DMSO
groups could be reduced (Figure 6). These results sug-
gested that the down-regulation of MICA/B expression
level by the activated UPR weakened the killing activities
of NK cells against HCC.
Discussion
Major histocompatibility complex class I-related chain A
and B (MICA/B) are stress-inducible ligands that bind to
the immunoreceptor NKG2D and play an important role
in tumor immunity [16]. In humans, MICA/B is rarely
expressed in healthy cells, but a broad expression in car-
cinoma cells, such as colorectal [17,18], breast [19], pan-
creatic cancers [20] and hepatocellular carcinoma [21].
Previous studies showed that the serum level of soluble
MICA (sMICA) is an independent prognostic factor for
advanced hepatocellular carcinoma [22], and the inter-
action of NKG2D and corresponding ligands MICA/B
may play an important role in immune-surveillance
against cholangiocarcinoma and hepatocellular carcinoma
[23,24]. However, the correlation between hepatocellular
carcinoma progression and membrane-bound MICA/B
expression has not been well explored.
In line with previous studies, we confirmed that the
expression of MICA/B could be detected in HCC cells
and negatively associated with HCC TNM stage. We
also provided evidence that low expression levels of
MICA/B in human hepatoma tissues were significantly
associated with a poorer outcome in patients with HCC.
Our results showed the patients with low MICA/B expres-
sion are usually at a significantly higher risk of tumor pro-
gression and shorter overall survival.
Previous studies documented that the expression of
NKG2D ligands are up-regulated through a variety of
stimuli that have been collectively termed “cellular
stress”, such as cellular transformation, viral infection,
and/or DNA damage [25,26], and the upregulation of
MICA/B in distressed cells may alert the immune system
that the cells are undergoing pathological changes and
enhance the innate immune function. However there has
been no report of whether the UPR in HCC could regu-
late the expression levels of the ligands for NK cell acti-
vating receptors and affect the sensitivity to NK cell
Figure 6 Reduced cytotoxic activity of NK cells against hepatoma cells treated with TM for 24 h. The susceptibility of SMMC7721 cells
(left) and HepG2 cells (right) to NK cell cytolysis was determined using the LDH cytotoxicity assay. The NK cells were incubated with SMMC7721
or HepG2 cells at the indicated effecter/target ratios. Data were presented as means ± S.D., **P < 0.01.
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HCC coupled with poor blood supply usually leads to
hypoxia, decreased glucose, nutrition supply and UPR in
tumor tissues during HCC progression [11]. Acting as a
cytoprotective response against malignant cells, the UPR
reduces the accumulation of unfolded cellular proteins
and restores normal ER function. Our study represents
the first demonstration that activated unfolded protein
response (UPR) could down-regulate the protein expres-
sion level of MICA/B in HCC cells. Besides, another im-
portant finding of the present study is that GRP78, a
marker of UPR, was significantly related with tumor
TNM stage and negatively correlated with MICA/B ex-
pression level in HCC tissues. This finding suggested that
activation of the UPR was negatively correlated with
MICA/B expression in HCC tissues and consistent with
the results from HCC cell lines.
Although the treatment of different hepatoma cell lines
with the ER stress inducer tunicamycin reduced the pro-
tein levels of MICA/B on hepatoma cells, this is not ac-
companied by a reduction of MICA/B mRNA during the
UPR. We conjectured that the inhibition of protein
expression was likely mediated by post-transcriptional
mechanisms. Further experiments confirmed this conjec-
ture: the reduction of MICA/B expression in hepatoma
cells during the UPR was at least partly due to proteaso-
mal degradation. However, the regulation mechanisms re-
sponsible for the upregulation of MICA/B transcription
require further investigation.
To further clarify the function of MICA/B in hepatoma
cells during UPR, we assessed if reduced expression level
of MICA/B on hepatoma cells undergoing UPR had any
effects on NK cells cytotoxicity against hepatoma cells.
The result showed that TM could attenuate the activity of
NK cells against the tumor, via mechanisms that can in-
volve a parallel action on NK cells and malignant cells,decreasing the expression of activating ligand that pro-
mote recognition and reducing the cytolytic activity of the
effect cells.
It should be noted that loss of the predominant membrane-
bound MICA/B is associated with progression to invasive
tumor or to progressively higher grades [27]. On the other
hand, high MICA/B expression is inversely correlated with
survival in patients with pancreatic carcinoma [28]. These
reports suggest a fundamental difference in the involve-
ment of MICA/B -mediated immunity among various
types of tumors.
In conclusion, we provide novel information about MICA/
B in HCCs. Our results showed the HCC patients with
low MICA/B expression are usually at a significantly
higher risk of shorter overall survival. Furthermore, UPR
could downregulate MICA/B expression on hepatoma
cells, and thereby rendered them less susceptible to NK
cytolysis. This suggests that reducing UPR may have an
impact on increasing MICA/B expression and enhancing
NK cytotoxicity and thus may be an useful strategy in
treatment of HCC.
Additional file
Additional file 1: Table S1. Clinical pathological characteristics of 96
HCC cases.
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